Nanoveu Ltd (ASX: NVU) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Nanoveu Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$26.76 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
504.92 million
Earnings per share
-0.006
Dividend per share
N/A
Year To Date Return
N/A
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Nanoveu Ltd (ASX: NVU)
Latest News
Share Gainers
Guess which ASX microcap stock just rocketed 109% on a new deal!
Share Market News
Nanovue (ASX:NVU) share price rockets 89% on new customer win
Share Market News
Why the Nanoveu (ASX:NVU) share price is roaring 14% higher
NVU ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Nanoveu Ltd
Nanoveu Ltd is a technology company developing a range of products for mobile phones and other digital displays. The company's wholly-owned, flagship product is its Nanoshield antiviral protector which is available in a variety of mobile phone screen covers, mobile phone cases and as a commercial film capable of being applied to a number of surfaces. The product is a clear plastic containing a layer of charged copper nanoparticles which have antiviral and antimicrobial properties. The Group deploys nanotechnology applications for consumer devices.
NVU Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 25 Oct 2024 | $0.05 | $0.00 | 0.00% | 6,444,376 | $0.05 | $0.06 | $0.05 |
| 24 Oct 2024 | $0.05 | $-0.01 | -17.86% | 11,415,314 | $0.06 | $0.06 | $0.05 |
| 23 Oct 2024 | $0.06 | $-0.01 | -15.15% | 22,656,584 | $0.06 | $0.06 | $0.06 |
| 22 Oct 2024 | $0.07 | $0.02 | 41.67% | 80,867,294 | $0.06 | $0.07 | $0.06 |
| 21 Oct 2024 | $0.05 | $0.01 | 23.26% | 7,637,265 | $0.05 | $0.05 | $0.05 |
| 18 Oct 2024 | $0.04 | $0.00 | 0.00% | 12,141,513 | $0.04 | $0.05 | $0.04 |
| 17 Oct 2024 | $0.04 | $0.00 | 0.00% | 4,722,064 | $0.04 | $0.04 | $0.03 |
| 16 Oct 2024 | $0.04 | $-0.01 | -21.74% | 11,332,533 | $0.05 | $0.05 | $0.04 |
| 15 Oct 2024 | $0.05 | $0.02 | 93.02% | 46,055,074 | $0.05 | $0.05 | $0.04 |
| 10 Oct 2024 | $0.02 | $0.00 | 0.00% | 439,664 | $0.02 | $0.02 | $0.02 |
| 03 Oct 2024 | $0.02 | $0.00 | 0.00% | 620 | $0.02 | $0.02 | $0.02 |
| 30 Sep 2024 | $0.02 | $0.00 | 0.00% | 219,376 | $0.02 | $0.02 | $0.02 |
| 26 Sep 2024 | $0.02 | $0.00 | 0.00% | 278 | $0.02 | $0.02 | $0.02 |
| 25 Sep 2024 | $0.02 | $0.00 | 0.00% | 109,188 | $0.02 | $0.02 | $0.02 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 28 Jun 2024 | David Pevcic | Issued | 5,000,000 | $90,000 |
Issue of securities. 6,625,000 Performance Rights
|
| 28 Jun 2024 | Michael Winlo | Issued | 2,500,000 | $45,000 |
Issue of securities. 3,500,000 Rights
|
| 28 Jun 2024 | Steven Apedaile | Issued | 5,000,000 | $90,000 |
Issue of securities. 6,030,000 Performance Rights
|
| 28 Jun 2024 | Teck Eng (Alfred) Chong | Issued | 5,000,000 | $90,000 |
Issue of securities. 8,162,500 Rights
|
| 12 Jun 2024 | Michael Winlo | Expiry | 1,000,000 | $23,000 |
As advised by the company. 1,000,000 - Performance Rights
Expiry of Performance Rights |
| 12 Jun 2024 | Teck Eng (Alfred) Chong | Expiry | 3,062,500 | $70,437 |
As advised by the company. 3,162,500 - Performance Rights
Performance Rights did not achieve its milestones and expired on 04/04/2024 |
| 12 Jun 2024 | David Pevcic | Expiry | 1,625,000 | $37,375 |
As advised by the company. 1,625,000 - Performance Rights
Expiry of Performance Rights |
| 12 Jun 2024 | Steven Apedaile | Expiry | 1,050,000 | $24,150 |
As advised by the company. 1,030,000 - Performance Rights
|
| 07 Mar 2024 | Steven Apedaile | Expiry | 75,000 | $1,725 |
As advised by the company. 2,080,000 Performance Rights, expired
|
| 07 Mar 2024 | Teck Eng (Alfred) Chong | Expiry | 850,000 | $19,550 |
As advised by the company. 62,25,000 Rights, Expired
|
| 07 Mar 2024 | Steven Apedaile | Expiry | 100,035 | $2,300 |
Options expired.
|
| 07 Mar 2024 | Teck Eng (Alfred) Chong | Expiry | 250,000 | $5,750 |
Options expired.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Steven James Apedaile | Non-Executive Director | May 2018 |
Mr Apedaile has worked in the accounting profession for over 30 years, 25 of which were spent in Hong Kong with the first 7 years with KPMG Hong Kong and then 18 years with Horwath Hong Kong. Steven has experience in all facets of international business, corporate finance and forensic accounting services.
|
| Mr Teck Eng (Alfred) Chong | FounderChief Executive OfficerManaging Director | Feb 2018 |
Mr Chong is the Founder of Nanoveu. He has a history of building companies and executing trade sales in California and Singapore. Alfred moved back to Asia in 1997 and was the Asia Pacific CEO for Atex Media Command, a global provider of solutions and services to the media industry; CEO for THISS Technologies Inc, a satellite communications company; CEO for 121View, a digital signage company; and CMO at 3D International before founding Nanoveu. The Singapore American Business Association in the United States named Alfred Entrepreneur of the Year and the San Francisco Chronicle named Alfred as one of the twenty foreign born high technology visionaries who have helped to make the San Francisco Bay Area the world's technology centre.
|
| Dr Michael Winlo | Non-Executive Director | Mar 2023 |
Dr Winlo has experience in leading high-growth teams across the biotech, pharmaceutical and technology sectors. Michael is also a Director and former CEO of Linear Clinical Research, a world class provider of early and late stage pharmaceutical trials. Prior to this he was the health lead for Palantir Technologies (Silicon Valley), one of the worlds big data companies. There, he led deployments for health and government organisations across the US and UK.
|
| Dr David Pevcic | Non-Executive ChairmanNon-Executive Director | Feb 2023 |
Dr Pevcic is a medical doctor and businessman, with a principal focus on the resources and technology sectors.
|
| Mrs Naomi Haydari | Chief Financial OfficerCompany Secretary | Jun 2023 |
-
|
| Naomi Haydari | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Sufian Ahmad | 74,221,817 | 16.65% |
| Bilal Ahmad | 54,623,529 | 12.26% |
| Alfred Chong | 43,337,999 | 9.72% |
| Kobala Investments Pty Ltd <Fernando Edward Family A/C> | 19,287,310 | 4.33% |
| Clayton Capital Pty Ltd | 14,705,650 | 3.30% |
| Dr Rosamund Julian Banyard & Mr Phillip Stanley Holten <R Banyard Super Fund A/C> | 13,767,563 | 3.09% |
| Bnp Paribas Noms Pty Ltd Uobkh A/C R'Miers | 12,727,500 | 2.86% |
| Mr Ahmed Noman | 8,125,966 | 1.82% |
| Citicorp Nominees Pty Limited | 7,770,724 | 1.74% |
| Mr Robert Anthony Martin <Martin Family A/C> | 7,500,000 | 1.68% |
| Bergen Global Opportunity Fund Lp | 7,500,000 | 1.68% |
| Mr Fadi Diab | 7,352,941 | 1.65% |
| Mr Dean Brett Blankfield <Dean Blankfield A/C> | 5,961,538 | 1.34% |
| Mr Phillip Stanley Holten | 5,733,153 | 1.29% |
| Mr Siavash Khosrowshahi & Mrs Zahra Nahid Khosrowshahi <S Khosrowshahi Family A/C> | 5,530,000 | 1.24% |
| Hendrik Antoon Limited | 5,345,438 | 1.20% |
| Mr Agha Shahzad Pervez | 4,705,883 | 1.06% |
| Netwealth Investments Limited <Wrap Services A/C> | 4,402,761 | 0.99% |
| Mr Mobeen Iqbal | 4,330,340 | 0.97% |
| Mr Corey Jay Sanders | 3,874,466 | 0.87% |
| Tantula Pty Ltd <Edwards Family S/F A/C> | 3,857,349 | 0.87% |
